Arbor Vita

Executive Summary

Arbor Vita Corporation is a Fremont, California-based biotechnology company specializing in rapid diagnostics for infectious diseases and cancers using its proprietary PDZ proteomics platform and monoclonal antibody library. The company has commercialized FDA-approved tests, including a rapid avian influenza (H5N1) test and the OncoE6™ Cervical Test for HPV-driven cervical cancer. Arbor Vita's point-of-care solutions address critical unmet needs in global health, offering fast and accurate detection in resource-limited settings. With a focus on leveraging its proteomics expertise, the company aims to expand its diagnostic pipeline to combat emerging infectious threats and improve cancer screening outcomes. Although privately held and with limited public financial data, Arbor Vita's approved products and established platform position it as a niche player in the diagnostics space, with potential for growth through regulatory approvals and strategic partnerships. The company's long-term success hinges on market adoption and broadening its test menu to address high-burden diseases.

Upcoming Catalysts (preview)

• Q4 2026FDA Clearance or CE Marking for Next-Generation OncoE6™ Test60% success
• Q2 2026Strategic Partnership for Global Distribution of Avian Influenza Test70% success
• Q1 2027Clinical Data Readout for New PDZ-Based Diagnostic Panel40% success